Investigation of corneal autoantibodies in horses with immune mediated keratitis (IMMK)

Braus, Barbara K.; Miller, Ingrid; Kummer, Stefan; Kleinwort, Kristina J. H.; Hirmer, Sieglinde; Hauck, Stefanie M.; McMullen, Richard J.; Kerschbaumer, M.; Deeg, Cornelia A.

doi:10.1016/j.vetimm.2017.04.002

Cited by 9 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In one study, researchers identified maspin in the corneas of horses with immune-related keratitis(IMMK), which is a tumor suppressor protein that regulates cell migration, invasion and adhesion and is synthesized in many normal epithelial cells. They suggested that the etiology of IMMK in horses may be an autoimmune response, and maspin plays a role in it ( 29 , 30 ). Maspin has been identified in the human corneal epithelium, stroma and endothelium.…”

Section: Discussionmentioning

confidence: 99%

Immune-related keratitis is a rare complication associated with nivolumab treatment in a patient with advanced colorectal cancer: A case report

Shi

Li²,

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

BackgroundImmunotherapy has been widely used to treat Colorectal cancer but has also observe some immune-related adverse effects. With proper treatment, most irAE can be solved and the effect of immunotherapy will not be affected by temporary immunosuppression. However, there are few reports about corneal irAE, and the current understanding of irAE is incomplete. Here we report a metastatic colorectal cancer case of immune-related keratitis caused by nivolumab and to explore the occurrence of immune-related keratitis.Case descriptionHere we report the case of a 49-year-old man with mCRC who had no previous ocular disease but developed immune-related ulcerative keratitis after treatment with nivolumab. We summarize a large amount of literature to discuss the mechanism of immune-related keratitis. In addition, we conclude a method that may be used to detect the occurrence of immune keratitis, by monitoring MMPs and maspin in patients treated with nivolumab. We believe immune-related keratitis may be a rare complication of nivolumab in the treatment of mCRC. The effect of simple anti-infective therapy and repair-promoting drugs was not obvious, but the effect of glucocorticoid combined with autologous serum was significant.ConclusionThe mechanism of immune-related keratitis is that nivolumab destroys the immune microenvironment and ACAID, and affects corneal healing. Patients who use nivolumab can prevent immune keratitis by testing MMPs and maspin. The occurrence of immune keratitis may be a good indicator of the efficacy of ICI, and further study can be done in the follow-up.

show abstract

Section: Discussionmentioning

confidence: 99%

Immune-related keratitis is a rare complication associated with nivolumab treatment in a patient with advanced colorectal cancer: A case report

Shi

Li²,

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…As a drug, it is used in human and veterinary medicine transplantation procedures as well as the broad spectrum of immune-mediated inflammatory diseases (IMIDs) due to its strong immunosuppressive potency [ 11 , 12 ]. However, due to cyclosporine’s physicochemical properties, its administration may cause several side effects including hepatotoxic, cardiotoxic, nephrotoxic, and neurotoxic effects [ 12 ] Therefore, new cyclosporine A sustained delivery implants in veterinary ophthalmology are essential to ensure high bioavailability and long-term release with minimally invasive implantation procedures, especially in non-cooperative horses with less committed owners [ 7 , 9 , 13 , 14 , 15 , 16 ].…”

Section: Introductionmentioning

confidence: 99%

PLDLA/TPU Matrix Enriched with Cyclosporine A as a Therapeutic Platform for Immune-Mediated Keratitis (IMMK) in Horses

Padjasek

Cisło-Sankowska

Lis-Bartos

et al. 2023

IJMS

View full text Add to dashboard Cite

The purpose of this study was to describe the use of PLDLA/TPU matrix enriched with cyclosporine A (CsA) as a therapeutic platform in horses with immune-mediated keratitis (IMMK) with an in vitro evaluation CsA release and degradation of the blend as well as determination of the safety and efficacy of that platform used in the animal model. The kinetics of the CsA release from matrices constructed of thermoplastic polyurethane (TPU) polymer and a copolymer of L-lactide with DL-lactide (PLDLA) (80:20) in the TPU (10%) and a PLDL (90%) polymer blend were studied. Moreover, we used the STF (Simulated Tear Fluid) at 37 °C as a biological environment to assess the CsA release and its degradation. Additionally, the platform described above was injected subconjunctival in the dorsolateral quadrant of the globe after standing sedation of horses with diagnosed superficial and mid-stromal IMMK. The obtained results indicated that the CsA release rate in the fifth week of the study increased significantly by the value of 0.3% compared to previous weeks. In all of the cases, the TPU/PLA doped with 12 mg of the CsA platform effectively reduced the clinical symptoms of keratitis, leading to the complete remission of the corneal opacity and infiltration four weeks post-injection. The results from this study showed that the PLDLA/TPU matrix enriched with the CsA platform was well tolerated by the equine model and effective in treating superficial and mid-stromal IMMK.

show abstract

Diseases of the Equine Cornea

Brooks¹,

Plummer²

2022

Equine Ophthalmology

View full text Add to dashboard Cite

Investigation of corneal autoantibodies in horses with immune mediated keratitis (IMMK)

Cited by 9 publications

References 26 publications

Immune-related keratitis is a rare complication associated with nivolumab treatment in a patient with advanced colorectal cancer: A case report

Immune-related keratitis is a rare complication associated with nivolumab treatment in a patient with advanced colorectal cancer: A case report

PLDLA/TPU Matrix Enriched with Cyclosporine A as a Therapeutic Platform for Immune-Mediated Keratitis (IMMK) in Horses

Diseases of the Equine Cornea

Contact Info

Product

Resources

About